DDL 2025 – The Next Chapter in Inhalation
• The pressure of speed to clinic is continuing to increase. Biotechs are under more pressure, and therefore the CDMOs supporting them must evolve too
• The pressure of speed to clinic is continuing to increase. Biotechs are under more pressure, and therefore the CDMOs supporting them must evolve too
• The pressure of speed to clinic is continuing to increase. Biotechs are under more pressure, and therefore the CDMOs supporting them must evolve too
What do biotechs need to know about oral solid dose manufacturing? Learn about how partnering with a CDMO can provide a competitive edge
We speak to Upperton’s Director of Pharmaceutical Sciences, Laura Mason, about the upcoming trends she sees emerging in the R&D lab.
A one-site CDMO is where GMP, R&D and manufacturing all operate on one site, making the movement of projects streamlined.
Tech transfer in oral solid dose (OSD) manufacturing is one of the most critical, and often underestimated, phases in the drug development lifecycle. For CDMOs, it’s a moment where scientific precision meets operational discipline.
By using our framework , sponsors can identify partners who don’t just deliver projects, but build relationships that last.
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
The nose to brain pathway can be leveraged to unlock new therapeutic possibilities. Learn about the opportunities of N2B delivery.
CPHI Frankfurt is one of the most anticipated events in the pharmaceutical calendar. Upperton is proud to be exhibiting.